Page 1

☑ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 FORM 40 - F REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ANNUAL REPORT PURSUANT TO SECTION 13 ( a ) OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30 , 2021 Commission File Number 001-39530 IMMUNOPRECISE ANTIBODIES LTD . ( Exact name of Registrant as specified in its charter ) Not applicable ( Translation of Registrant's name into English ( if applicable ) ) British Columbia ( Province or other jurisdiction of incorporation or organization ) 8731 98-1508109 ( Primary Standard Industrial Classification Code Number ( if applicable ) ) ( I.R.S. Employer Identification Number ( if applicable ) ) 3204-4464 Markham Street Victoria , British Columbia V8Z 7X8 ( 250 ) 483-0308 ( Address and telephone number of Registrant's principal executive offices ) Immunoprecise Antibodies ( USA ) , Ltd. 4837 Amber Valley Parkway Suite 11 Fargo , ND 58104 ( 701 ) 353-0022 ( Name , address ( including zip code ) and telephone number ( including area code ) of agent for service in the United States ) Securities registered or to be registered pursuant to Section 12 ( b ) of the Act . Title of each class Common Shares , no par value Trading Symbol ( s ) IPA Name of each exchange on which registered The NASDAQ Stock Market LLC Securities registered or to be registered pursuant to Section 12 ( g ) of the Act : None . Securities for which there is a reporting obligation pursuant to Section 15 ( d ) of the Act : None . For annual reports , indicate by check mark the information filed with this Form : Annual Information Form > Audited Annual Financial Statements